CERE News and Press, Ceres Inc. From 06/04/24

2024-06-04 04:20:17 ET Summary Cerevel Therapeutics agreed to be acquired by AbbVie on 12/06/23 for $45/s or ~$8.7B. CERE stock closed on Friday, May 31st at $40.74/s. This presents investors with a potential arbitrage play of over 10% on a deal that should close within the next 3...

2024-06-03 20:03:51 ET Summary Soros Fund Management's 13F portfolio value decreased from $7.65B to $6.02B in Q1 2024. New stakes include Cloudflare Inc. Puts, Cerevel Therapeutics, and Aramark. Stake disposals include Apple Puts, PDD Holdings Puts, and SPDR Index Euro Stocks ...

NEW YORK, NY / ACCESSWIRE / May 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVie") (NYSE:ABBV). Investors who purchased Cerevel and continue to holdto the present are enco...

2024-05-19 01:40:13 ET Summary Top M&A stocks of the 32 funds I follow. US Steel, the top stock held by merger-focused funds. Juniper Networks the second top stock. The thing about merger arbitrage is that it is always changing. Sometimes it seems easy for deals ...

2024-05-09 00:53:36 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cerevel Therapeutics Hldg (NASDAQ: CERE ) just reported results for the second quarter of 2024. Cerevel Therapeutics Hldg reported earnings per share of -73 cents. This wa...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...

2024-04-25 08:00:00 ET Summary Polaris Capital Management, LLC is a leading global value equity manager, serving the investment needs of institutions and individuals since 1995. Polaris has one of the longest global and international equity track records of any firm presently in opera...

2024-04-18 07:00:23 ET More on AbbVie AbbVie: Through Humira's Crisis Towards Solid Growth AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie: Bulletproof Fundamentals CVS favors Humira copycats hurting AbbVie’s market share: Evercore Ab...

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon’s potential to ...